InvestorsObserver
Sign Up Login

BCAB Bioatla Inc

$2.97 $0.00 (0.00%)
Add to Watchlist Compare
Overall

BCAB Stock Analysis Overview

What this means: InvestorsObserver gives Bioatla Inc (BCAB) an overall rank of 43, which is below average. Bioatla Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 43 means that 57% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

BCAB Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

BCAB Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

BCAB Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

BCAB Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

BCAB Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

BCAB Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

BCAB Stock Analysis Overview

What this means: InvestorsObserver gives Bioatla Inc (BCAB) an overall rank of 43, which is below average. Bioatla Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 43 means that 57% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full BCAB report

BCAB Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

BCAB Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

BCAB Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

BCAB Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

BCAB Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

BCAB Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Bioatla Inc (BCAB) Analyst Forecast

BCAB Price, Volume, Earnings, and Dividend Date

  • Last Price $2.97
  • Previous Close $2.97
  • Change $0.00
  • Open $3.01
  • Volume 599,000
  • Avg. Volume (100-day) 682,995
  • Market Cap 111,119,354
  • Days Range 2.88 - 3.08
  • 52-week Range 2.01 - 47.86
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 08/12/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 2.324
  • PEG Ratio —

Bioatla Inc (BCAB) Company Description

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs.

Bioatla Inc (BCAB) Stock Chart

View Interactive BCAB chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
F-Star Therapeutics Inc (FSTX) (FSTX) $6.27
Arcutis Biotherapeutics Inc (ARQT) (ARQT) $22.03
Chinook Therapeutics Inc (KDNY) (KDNY) $17.99
Evofem Biosciences Inc (EVFM) (EVFM) $1.07
Cogent Biosciences Inc (COGT) (COGT) $8.90
Chemocentryx Inc (CCXI) (CCXI) $25.08
Veru Inc (VERU) (VERU) $11.81
Aveo Pharmaceuticals (AVEO) (AVEO) $6.40
Fireman B.V. (IFRX) (IFRX) $1.52
Geron Corp (GERN) (GERN) $1.50